UvA-DARE ( Digital Academic Repository ) Immunogenicity of therapeutic antibodies

Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

[1]  With Complement , 2018, Journal of Innate Immunity.

[2]  T. Takeuchi,et al.  Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis , 2017, Modern rheumatology.

[3]  G. D'Haens,et al.  Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies , 2017, Annals of the rheumatic diseases.

[4]  J. Cyster,et al.  Germinal centers: programmed for affinity maturation and antibody diversification. , 2017, Current opinion in immunology.

[5]  J. Killestein,et al.  Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. , 2017, The Journal of allergy and clinical immunology.

[6]  P. Miossec,et al.  Selected cytokine pathways in rheumatoid arthritis , 2017, Seminars in Immunopathology.

[7]  A. Filer,et al.  Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts , 2017, Arthritis Research & Therapy.

[8]  L. Mouthon,et al.  Mechanisms of action of intravenous immunoglobulin. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[9]  S. Sidhu,et al.  Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds , 2017, Front. Immunol..

[10]  V. Jiménez‐Yuste,et al.  New findings on inhibitor development: from registries to clinical studies , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  R. Loebbert,et al.  Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT‐981 Against IL‐1α and IL‐1β in Healthy Subjects and Patients With Osteoarthritis of the Knee , 2016, Journal of clinical pharmacology.

[12]  A. Manning,et al.  Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors , 2016, Science Translational Medicine.

[13]  M. Neurath,et al.  Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases , 2016, World journal of gastroenterology.

[14]  C. Klein,et al.  Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. , 2016, Protein engineering, design & selection : PEDS.

[15]  M. Reth,et al.  Molecular requirements of the B‐cell antigen receptor for sensing monovalent antigens , 2016, The EMBO journal.

[16]  R. Detels,et al.  Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. , 2016, Cytokine.

[17]  N. Zhang,et al.  A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab , 2016, Annals of the rheumatic diseases.

[18]  D. Furst,et al.  Premedication prevents infusion reactions and improves retention rate during infliximab treatment , 2016, Clinical Rheumatology.

[19]  P. Parren,et al.  Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen. , 2016, Molecular cell.

[20]  H. Reichmann,et al.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies , 2016, Journal of Neuroinflammation.

[21]  T. Wyant,et al.  Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance , 2016, Journal of immunology research.

[22]  D. Tarlinton,et al.  Regulation of germinal center responses, memory B cells and plasma cell formation-an update. , 2016, Current opinion in immunology.

[23]  L. Punzi,et al.  The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. , 2016, Joint, bone, spine : revue du rhumatisme.

[24]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[25]  E. Scaioli,et al.  How to predict clinical relapse in inflammatory bowel disease patients. , 2016, World journal of gastroenterology.

[26]  J. Braun,et al.  Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study , 2016, Arthritis Research & Therapy.

[27]  Sandeep Kumar,et al.  The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies. , 2015, Journal of pharmaceutical sciences.

[28]  U. Jappe,et al.  B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera , 2015, Journal of Translational Medicine.

[29]  J. Ceuppens,et al.  Defining thresholds of specific IgE levels to grass pollen and birch pollen allergens improves clinical interpretation. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[30]  T. Huizinga,et al.  Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. , 2015, Journal of managed care & specialty pharmacy.

[31]  L. Peyrin-Biroulet,et al.  IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment , 2015, European journal of gastroenterology & hepatology.

[32]  M. Carrasco-Triguero.  Insights on the immunogenicity of antibody-drug conjugates. , 2015, Bioanalysis.

[33]  F. Nantel,et al.  Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry , 2015, The Journal of Rheumatology.

[34]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[35]  Theo Rispens,et al.  Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.

[36]  K. Thorlund,et al.  Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs , 2015, Expert review of gastroenterology & hepatology.

[37]  S. Vermeire,et al.  Immunogenicity to infliximab is associated with HLA-DRB1 , 2015, Gut.

[38]  A. van Leeuwen,et al.  Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. , 2015, Journal of immunological methods.

[39]  Honghui Zhou,et al.  Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety , 2015, Journal of clinical pharmacology.

[40]  M. Nurmohamed,et al.  Key findings towards optimising adalimumab treatment: the concentration-effect curve. , 2015, Annals of the rheumatic diseases.

[41]  T. Craig,et al.  Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) , 2015, Expert review of clinical immunology.

[42]  U. Klein,et al.  Dynamics of B cells in germinal centres , 2015, Nature Reviews Immunology.

[43]  K. Yoshizaki,et al.  Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy , 2015, Expert opinion on drug metabolism & toxicology.

[44]  Xavier Montalban,et al.  Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles , 2014, Neurology: Neuroimmunology & Neuroinflamm.

[45]  T. Anchordoquy,et al.  Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. , 2014, Drug discovery today.

[46]  L. Aarden,et al.  The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region , 2014, Annals of the rheumatic diseases.

[47]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[48]  L. Aarden,et al.  Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies♦ , 2014, The Journal of Biological Chemistry.

[49]  R. Jordan,et al.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo , 2014, mAbs.

[50]  D. Forthal,et al.  Functions of Antibodies , 2014, Microbiology spectrum.

[51]  G. Wolbink,et al.  Antibodies to IgG4 Hinge Can Be Found in Rheumatoid Arthritis Patients During All Stages of Disease and May Exacerbate Chronic Antibody‐Mediated Inflammation , 2014, Arthritis & rheumatology.

[52]  V. Devanarayan,et al.  Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations , 2014, The AAPS Journal.

[53]  Markus F. Neurath,et al.  Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.

[54]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[55]  G. Vidarsson,et al.  Dynamics of Inter-heavy Chain Interactions in Human Immunoglobulin G (IgG) Subclasses Studied by Kinetic Fab Arm Exchange , 2014, The Journal of Biological Chemistry.

[56]  A. Moss,et al.  Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[57]  N. Cnubben,et al.  The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab , 2014, Journal of Immunotoxicology.

[58]  Shannon L Meeks,et al.  Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. , 2013, Blood.

[59]  M. Cogné,et al.  AID-induced remodeling of immunoglobulin genes and B cell fate , 2013, Oncotarget.

[60]  A. van Leeuwen,et al.  Drug interference in immunogenicity assays depends on valency. , 2013, Journal of pharmaceutical and biomedical analysis.

[61]  U. Kopylov,et al.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.

[62]  I. Mellman.  Dendritic Cells: Master Regulators of the Immune Response , 2013, Cancer Immunology Research.

[63]  Ya-jun Guo,et al.  Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view , 2013 .

[64]  A. Rothe,et al.  Monoclonal antibody treatments for rheumatoid arthritis , 2013, Expert opinion on biological therapy.

[65]  J. Gómez-Reino,et al.  Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. , 2013, Seminars in arthritis and rheumatism.

[66]  A. Serone,et al.  Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 , 2013, Journal of Clinical Immunology.

[67]  L. Essioux,et al.  The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. , 2013, Rheumatology.

[68]  J. Carvalho,et al.  Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis , 2013, Rheumatology International.

[69]  G. Wolbink,et al.  Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography. , 2013, Analytical biochemistry.

[70]  L. Xue,et al.  Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics , 2013, The AAPS Journal.

[71]  M. Milla,et al.  Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[72]  P. Rutgeerts,et al.  Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.

[73]  W. Hennink,et al.  The Immunogenicity of Polyethylene Glycol: Facts and Fiction , 2013, Pharmaceutical Research.

[74]  Huub Schellekens,et al.  The Immunogenicity of Polyethylene Glycol: Facts and Fiction , 2013, Pharmaceutical Research.

[75]  K. Bendtzen,et al.  Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[76]  Surinder Kaur,et al.  Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. , 2013, Bioanalysis.

[77]  J. Hillert,et al.  Characterization of anti-natalizumab antibodies in multiple sclerosis patients , 2013, Multiple sclerosis.

[78]  F. Barkhof,et al.  Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis , 2013, Multiple sclerosis.

[79]  M. Pirmohamed,et al.  Challenges and approaches for the development of safer immunomodulatory biologics , 2013, Nature Reviews Drug Discovery.

[80]  Z. Rao,et al.  Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab* , 2013, The Journal of Biological Chemistry.

[81]  P. V. Schouwenburg,et al.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[82]  P. Chamberlain.  Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. , 2013, Bioanalysis.

[83]  M. Trojano,et al.  The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study , 2013, Journal of Neurology.

[84]  T. Platts-Mills,et al.  IgE Production to α-Gal Is Accompanied by Elevated Levels of Specific IgG1 Antibodies and Low Amounts of IgE to Blood Group B , 2013, PloS one.

[85]  M. Newkirk,et al.  A rheumatoid factor paradox: inhibition of rituximab effector function , 2013, Arthritis Research & Therapy.

[86]  L. Aarden,et al.  Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation , 2013, Annals of the rheumatic diseases.

[87]  P. Creeke,et al.  Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis , 2013, Therapeutic advances in neurological disorders.

[88]  Liwu Li,et al.  Molecular Mechanism Responsible for the Priming of Macrophage Activation* , 2012, The Journal of Biological Chemistry.

[89]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[90]  R. Eliakim,et al.  Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies , 2012, Inflammatory bowel diseases.

[91]  S. Tatarewicz,et al.  Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. , 2012, Journal of immunological methods.

[92]  M. Carroll,et al.  Regulation of humoral immunity by complement. , 2012, Immunity.

[93]  M. Nurmohamed,et al.  IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients , 2012, Journal of Clinical Immunology.

[94]  M. Nurmohamed,et al.  Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner , 2012, Annals of the rheumatic diseases.

[95]  F. Breden,et al.  The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease , 2012, Genes and Immunity.

[96]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[97]  M. Shlomchik,et al.  Germinal center selection and the development of memory B and plasma cells , 2012, Immunological reviews.

[98]  Theo Rispens,et al.  Immunogenicity of biological therapeutics: from assay to patient , 2012, Current opinion in rheumatology.

[99]  D. Myszka,et al.  Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display , 2012, mAbs.

[100]  D. Strayer,et al.  Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. , 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[101]  S. Appenzeller,et al.  Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis , 2012, Rheumatology International.

[102]  K. Bendtzen,et al.  Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[103]  L. Aarden,et al.  Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. , 2012, Journal of immunological methods.

[104]  B. Aggarwal,et al.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. , 2012, Blood.

[105]  J. Pérez-Ruixo,et al.  Immunogenicity of panitumumab in combination chemotherapy clinical trials , 2011, BMC clinical pharmacology.

[106]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[107]  Miho Suzuki,et al.  Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice , 2011, Rheumatology International.

[108]  L. Aarden,et al.  Differential effect of drug interference in immunogenicity assays. , 2011, Journal of immunological methods.

[109]  E. Martı́n-Mola,et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.

[110]  L. Trouw,et al.  Complement activation by (auto-) antibodies. , 2011, Molecular immunology.

[111]  S. Fischer,et al.  Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. , 2011, Journal of pharmaceutical and biomedical analysis.

[112]  María Vázquez-Rey,et al.  Aggregates in monoclonal antibody manufacturing processes , 2011, Biotechnology and bioengineering.

[113]  K. Bendtzen,et al.  Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[114]  F. Marmé,et al.  Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites , 2011, International journal of cancer.

[115]  M. Wuhrer,et al.  Enrichment of Sialylated IgG by Lectin Fractionation Does Not Enhance the Efficacy of Immunoglobulin G in a Murine Model of Immune Thrombocytopenia , 2011, PloS one.

[116]  T. Rispens,et al.  Mechanism of immunoglobulin G4 Fab-arm exchange. , 2011, Journal of the American Chemical Society.

[117]  P. Goupille,et al.  Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study , 2011, Arthritis research & therapy.

[118]  R. Jordan,et al.  The Origins, Specificity, and Potential Biological Relevance of Human Anti-IgG Hinge Autoantibodies , 2011, TheScientificWorldJournal.

[119]  P. Baeuerle,et al.  Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.

[120]  P. V. van Riel,et al.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries , 2011, Annals of the rheumatic diseases.

[121]  T. Platts-Mills,et al.  The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. , 2011, The Journal of allergy and clinical immunology.

[122]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[123]  M. Kosmač,et al.  Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab , 2011, Pediatric Research.

[124]  R. Dubridge,et al.  The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site , 2011, Genes and Immunity.

[125]  B. Dijkmans,et al.  Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study , 2010, Arthritis research & therapy.

[126]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[127]  L. Aarden,et al.  A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. , 2010, Journal of immunological methods.

[128]  G. Wolbink,et al.  Therapy: Immunogenicity of biologic therapies—we need tolerance , 2010, Nature Reviews Rheumatology.

[129]  R. Nezlin.  Interactions between immunoglobulin G molecules. , 2010, Immunology letters.

[130]  K. Mann,et al.  The "normal" factor VIII concentration in plasma. , 2010, Thrombosis research.

[131]  K. Stubenrauch,et al.  Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. , 2010, Clinical therapeutics.

[132]  A. Compston,et al.  A Novel Strategy To Reduce the Immunogenicity of Biological Therapies , 2010, The Journal of Immunology.

[133]  Bill Pikounis,et al.  Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α , 2010, mAbs.

[134]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[135]  J. Hess,et al.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients , 2010, British journal of clinical pharmacology.

[136]  Steven J Swanson,et al.  Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. , 2010, Journal of immunological methods.

[137]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[138]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[139]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[140]  R. Jordan,et al.  Cleavage of IgGs by proteases associated with invasive diseases , 2010, mAbs.

[141]  N. Tsuji,et al.  Prevalence of human anti-mouse antibodies (HAMAs) in routine examinations. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[142]  E. D. De Jong,et al.  Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. , 2010, Archives of dermatology.

[143]  S. Bahram,et al.  A Novel Heterophilic Antibody Interaction Involves IgG4 , 2010, Scandinavian journal of immunology.

[144]  P. Nurden,et al.  Thrombocytopenia after abciximab use results from different mechanisms , 2010, Thrombosis and Haemostasis.

[145]  D. Zaller,et al.  IgG2m4, an engineered antibody isotype with reduced Fc function , 2009, mAbs.

[146]  M. Shima,et al.  Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. , 2009, Seminars in thrombosis and hemostasis.

[147]  G. Klee.  Human anti-mouse antibodies. , 2009, Archives of pathology & laboratory medicine.

[148]  D. Zillikens,et al.  Immunogenicity of rituximab in patients with severe pemphigus. , 2009, Clinical immunology.

[149]  D. Czajkowsky,et al.  The human IgM pentamer is a mushroom-shaped molecule with a flexural bias , 2009, Proceedings of the National Academy of Sciences.

[150]  K. Stubenrauch,et al.  Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. , 2009, Analytical biochemistry.

[151]  Naoko Yamane-Ohnuki,et al.  Production of therapeutic antibodies with controlled fucosylation , 2009, mAbs.

[152]  P. Rutgeerts,et al.  IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab , 2009, Pharmacogenetics and genomics.

[153]  E. Sasso,et al.  Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. , 2009, Clinical immunology.

[154]  T. Rispens,et al.  Human IgG4 Binds to IgG4 and Conformationally Altered IgG1 via Fc-Fc Interactions , 2009, The Journal of Immunology.

[155]  T. Rispens,et al.  Immunoglobulin G4: an odd antibody , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[156]  P. Baiardi,et al.  Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. , 2009, Clinical and experimental rheumatology.

[157]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[158]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[159]  B. Dijkmans,et al.  Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[160]  M. H. Ryan,et al.  Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs1 , 2008, The Journal of Immunology.

[161]  M. D. de Rie,et al.  Review and expert opinion on prevention and treatment of infliximab‐related infusion reactions , 2008, The British journal of dermatology.

[162]  L. Aarden,et al.  Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. , 2008, Current opinion in immunology.

[163]  S. Misbah,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[164]  T. Mayadas,et al.  Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes , 2008, Journal of leukocyte biology.

[165]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..

[166]  Yong-Sung Kim,et al.  Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. , 2007, Journal of molecular biology.

[167]  J. Salfeld,et al.  Isotype selection in antibody engineering , 2007, Nature Biotechnology.

[168]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[169]  M. Dougados,et al.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.

[170]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[171]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[172]  A. Vandenbark,et al.  Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients , 2007, Journal of Neuroimmunology.

[173]  S. Cessie,et al.  Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A , 2007, Journal of thrombosis and haemostasis : JTH.

[174]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[175]  B. Dijkmans,et al.  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation , 2007, Annals of the rheumatic diseases.

[176]  Li Yang,et al.  Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. , 2007, Analytical biochemistry.

[177]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[178]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[179]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[180]  P. Ligthart,et al.  The restricted use of IGHV3 superspecies genes in anti‐Rh is not limited to hyperimmunized anti‐D donors , 2006, Transfusion.

[181]  F. Armbruster,et al.  Immunogenicity, efficacy and adverse events of adalimumab in RA patients , 2006, Rheumatology International.

[182]  L. Aarden,et al.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[183]  G. Himmler,et al.  Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody. , 2006, Journal of pharmaceutical and biomedical analysis.

[184]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[185]  P. Nelson,et al.  Rheumatoid factors: what's new? , 2006, Rheumatology.

[186]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[187]  J. Bluestone,et al.  CTLA4Ig: bridging the basic immunology with clinical application. , 2006, Immunity.

[188]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[189]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[190]  A. Signorile,et al.  Comparison of two enzyme immunometric assays to measure tumor necrosis factor-alpha in human serum. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[191]  J. Twisk,et al.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[192]  R. Baldassano,et al.  Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium , 2005, Inflammatory bowel diseases.

[193]  C. Wagner,et al.  Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.

[194]  G. Denardo,et al.  A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[195]  E. Keystone,et al.  Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. , 2004, The Journal of rheumatology.

[196]  C. Alessandri,et al.  Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement , 2004, Annals of the rheumatic diseases.

[197]  E. Veys,et al.  Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[198]  G. Burmester,et al.  Rheumatoid factor revisited , 2004, Current opinion in rheumatology.

[199]  M. Effron,et al.  Final results of the ReoPro readministration registry. , 2004, The American journal of cardiology.

[200]  J. R. Smith,et al.  Phagocytosis of opsonized apoptotic cells: roles for ‘old‐fashioned’ receptors for antibody and complement , 2004, Clinical and experimental immunology.

[201]  H. Schneider,et al.  Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display , 2004, Thrombosis and Haemostasis.

[202]  S. Plevy,et al.  The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.

[203]  G. Denardo,et al.  Human antiglobulin response to foreign antibodies: therapeutic benefit? , 2003, Cancer Immunology, Immunotherapy.

[204]  Andreas Plückthun,et al.  Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.

[205]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[206]  S. Edwards,et al.  Insoluble and soluble immune complexes activate neutrophils by distinct activation mechanisms: changes in functional responses induced by priming with cytokines , 2002, Annals of the rheumatic diseases.

[207]  I. Krull,et al.  Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. , 2001, Analytical biochemistry.

[208]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[209]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[210]  F. Yu,et al.  Immobilization of antibodies on ultraflat polystyrene surfaces. , 2000, Clinical chemistry.

[211]  R. O’Kennedy,et al.  Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. , 2000, Journal of immunological methods.

[212]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[213]  Capra,et al.  Molecular Characterization of the VH1‐Specific Variable Region Determinants Recognized by Anti‐Idiotypic Monoclonal Antibodies G6 and G8 , 1999, Scandinavian journal of immunology.

[214]  I. Kaplan,et al.  When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. , 1999, Clinical chemistry.

[215]  D. Kioussis,et al.  Elimination of the immunogenicity of therapeutic antibodies. , 1999, Journal of immunology.

[216]  R. Jefferis,et al.  Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. , 1998, Molecular immunology.

[217]  A. L. Wong,et al.  Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. , 1995, Journal of immunology.

[218]  H. Weisman,et al.  The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. , 1995, Molecular immunology.

[219]  J. Cavaillon,et al.  Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. , 1995, Journal of immunological methods.

[220]  A. Glas,et al.  Polymorphism and Utilization of Human VH Genes a , 1995, Annals of the New York Academy of Sciences.

[221]  L. Moroder,et al.  The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope. , 1995, Journal of immunology.

[222]  D. Lloyds,et al.  Neutrophil priming: the cellular signals that say 'amber' but not 'green'. , 1995, Immunology today.

[223]  A. Nisonoff.  On the nomenclature for V-region serological markers. , 1995, Immunology today.

[224]  R. Jefferis.  Nomenclature of V-region markers. , 1995, Immunology today.

[225]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[226]  M. Kazatchkine,et al.  Are lymphocytes concerned with our definition of idiotypes? , 1993, Immunology today.

[227]  E. Voss,et al.  The immunochemistry of sandwich ELISAs--VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denatured by passive adsorption. , 1993, Molecular immunology.

[228]  J. Baars,et al.  Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. , 1993, Journal of immunological methods.

[229]  N. K. Jerne,et al.  The Generative Grammar of the Immune System , 1993, The EMBO journal.

[230]  H. Kunkel,et al.  Anti‐Gammaglobulin Factors in Human Sera Revealed by Enzymatic Splitting of Anti‐Rh Antibodies , 1993 .

[231]  D. Goeddel,et al.  Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. , 1993, Biochemistry.

[232]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[233]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[234]  L. Chatenoud,et al.  PREDICTION OF SUCCESSFUL ALLOGRAFT REJECTION RETREATMENT WITH OKT31,2 , 1992, Transplantation.

[235]  H. Tabuchi,et al.  Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. , 1991, The Journal of biological chemistry.

[236]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[237]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[238]  E. Sasso,et al.  Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. , 1988, Journal of immunology.

[239]  L. Chatenoud,et al.  Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. , 1986, Journal of immunology.

[240]  L. Chatenoud,et al.  The human immune response to the OKT3 monoclonal antibody is oligoclonal. , 1986, Science.

[241]  H. Waldmann,et al.  Tolerance to rat monoclonal antibodies. Implications for serotherapy , 1986, The Journal of experimental medicine.

[242]  L. Itri,et al.  Safety and tolerance of recombinant interferon alfa‐2a (roferon®‐A) in Cancer Patients , 1986, Cancer.

[243]  U. Galili,et al.  A unique natural human IgG antibody with anti-alpha-galactosyl specificity , 1984, The Journal of experimental medicine.

[244]  B. S. Kim.  Mechanisms of idiotype suppression: Role of anti-idiotype antibody , 1982, Survey of immunologic research.

[245]  M. Daha,et al.  Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates. , 1982, Immunology.

[246]  A. Abbot,et al.  Long-term antigen retention by dendritic cells in the popliteal lymph node of immunized mice. , 1981, Immunology.

[247]  J. Engel,et al.  Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement. , 1980, The Biochemical journal.

[248]  J. Snick,et al.  Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen‐antibody complexes , 1978, European journal of immunology.

[249]  B. Vogelstein,et al.  Molecular determinants of immunogenicity: the immunon model of immune response. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[250]  O. Mellbye,et al.  Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. , 1971, Clinical and experimental immunology.

[251]  R. Ballieux,et al.  Antibody to Hereditary Human Gamma-Globulin (Gm) Factor Resulting from Maternal-Fetal Incompatibility , 1964, Science.

[252]  M. Heidelberger,et al.  THE PRECIPITIN REACTION BETWEEN TYPE III PNEUMOCOCCUS POLYSACCHARIDE AND HOMOLOGOUS ANTIBODY , 1935, The Journal of experimental medicine.

[253]  D. Calado,et al.  Germinal Centers , 2017, Methods in Molecular Biology.

[254]  John D. Isaacs,et al.  Cytokines in rheumatoid arthritis — shaping the immunological landscape , 2016, Nature Reviews Rheumatology.

[255]  I. Mikaelian,et al.  Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[256]  A. Zarrin,et al.  Antibody Isotype Switching in Vertebrates. , 2015, Results and problems in cell differentiation.

[257]  A. Hey.  History and Practice: Antibodies in Infectious Diseases , 2015, Microbiology spectrum.

[258]  P. Parren,et al.  Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. , 2013, Molecular immunology.

[259]  R. Kimberly,et al.  Fcy Receptor III on Human Neutrophils Allelic Variants Have Functionally Distinct Capacities , 2013 .

[260]  Theo Rispens,et al.  Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization , 2012 .

[261]  P. Goupille,et al.  Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. , 2012, British journal of clinical pharmacology.

[262]  D. Heijde,et al.  Clinical and epidemiological research , 2011 .

[263]  T. Rispens,et al.  Immunoglobulin G 4 : an odd antibody , 2011 .

[264]  F. Batista,et al.  The who, how and where of antigen presentation to B cells , 2009, Nature Reviews Immunology.

[265]  A. Lazarus,et al.  Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. , 2009, Hematology. American Society of Hematology. Education Program.

[266]  A. Verma.  The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .

[267]  P. Rutgeerts,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.

[268]  R. Mierau,et al.  Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis , 2006, Clinical chemistry and laboratory medicine.

[269]  H. Lilja,et al.  Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. , 2006, Analytical chemistry.

[270]  J. Plevris.  Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial , 2006 .

[271]  U. Galili.  The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. , 2005, Immunology and cell biology.

[272]  R. Jefferis,et al.  Immunogenic and antigenic epitopes of immunoglobulins XVII-monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors , 2004, Rheumatology International.

[273]  A. Lutterotti,et al.  Epitope specificity of neutralizing antibodies against IFN-beta. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[274]  M. Egmond,et al.  Chapter 2 The Fc receptor for IgA (FcαRI, CD89) , 2004 .

[275]  A. Perelson,et al.  Immunons revisited: binding of multivalent antigens to B cells. , 1997, Molecular immunology.

[276]  P. Bjorkman,et al.  Fc receptors and their interactions with immunoglobulins. , 1996, Annual review of cell and developmental biology.

[277]  T. Sauerbruch,et al.  A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha. , 1996, Journal of immunological methods.

[278]  R. Pain,et al.  The folding and assembly pathway of tumour necrosis factor TNF alpha, a globular trimeric protein. , 1995, European journal of biochemistry.

[279]  R. Jefferis.  What is an idiotype? , 1993, Immunology today.

[280]  A. Corti,et al.  Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. , 1992, The Biochemical journal.

[281]  G. D. de Lange,et al.  Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. , 1989, Experimental and clinical immunogenetics.

[282]  M. Walport,et al.  Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. , 1988, Arthritis and rheumatism.

[283]  T. Arakawa,et al.  Dissociation of recombinant tumor necrosis factor-alpha studied by gel permeation chromatography. , 1987, Biochemical and biophysical research communications.

[284]  N K Jerne,et al.  Towards a network theory of the immune system. , 1973, Annales d'immunologie.

[285]  A. Andriulli,et al.  Clinical and Experimental Gastroenterology Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress New Biologics in the Management of Crohn's Disease: Focus on Certolizumab Pegol , 2022 .

[286]  Annemarie Honegger,et al.  Biophysical Properties of Human Antibody Variable Domains , 2022 .

[287]  On the Stability of , 2022 .